written on 20.05.2014

What next for Pfizer? Perhaps a return to the popular breakup idea


So, Pfizer. What's Plan B? That's what investors are asking, now that CEO Ian Read's $117 billion bid for AstraZeneca hit a wall–and the promised trifecta of lower taxes, cost savings and promising drugs along with it.